doi: 10.1016/j.redox.2020.101731 63
Phase 2 clinical trials enrolled 338 participants across dose groups ranging from 1mg to 12mg weekly
En los estudios SURMOUNT para obesidad, produjo una prdida de peso promedio del 15-20% del peso corporal inicial, dependiendo de la dosis utilizada
When to Seek Help: Warning Signs While muscle changes during weight loss are normal, certain symptoms warrant prompt evaluation: Unexpected weakness or difficulty with previously manageable tasks New or worsening joint pain despite weight reduction Increased difficulty recovering from typical activities Balance changes or near-falls Significant changes in posture or movement patterns Early intervention for these warning signs can prevent more significant functional decline and allow continued progress toward health goals
to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition
SIDIAP contains records related to demographics, diagnoses (coded according to the International Classification of Diseases, 10th revision (ICD-10-CM)), therapeutic and requested procedures, physical examination results, routine measurements and laboratory tests
